These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31017050)

  • 1. Investigating specificity of the anti-hypertensive inhibitor WNK463 against With-No-Lysine kinase family isoforms via multiscale simulations.
    Jonniya NA; Kar P
    J Biomol Struct Dyn; 2020 Mar; 38(5):1306-1321. PubMed ID: 31017050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of structural and conformational properties of WNK kinase isoforms bound to an inhibitor: insights from molecular dynamic simulations.
    Jonniya NA; Sk MF; Kar P
    J Biomol Struct Dyn; 2022 Feb; 40(3):1400-1415. PubMed ID: 33016858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elucidating specificity of an allosteric inhibitor WNK476 among With-No-Lysine kinase isoforms using molecular dynamic simulations.
    Amarnath Jonniya N; Sk MF; Kar P
    Chem Biol Drug Des; 2021 Sep; 98(3):405-420. PubMed ID: 33969941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SPAK/OSR1 regulate NKCC1 and WNK activity: analysis of WNK isoform interactions and activation by T-loop trans-autophosphorylation.
    Thastrup JO; Rafiqi FH; Vitari AC; Pozo-Guisado E; Deak M; Mehellou Y; Alessi DR
    Biochem J; 2012 Jan; 441(1):325-37. PubMed ID: 22032326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dietary electrolyte-driven responses in the renal WNK kinase pathway in vivo.
    O'Reilly M; Marshall E; Macgillivray T; Mittal M; Xue W; Kenyon CJ; Brown RW
    J Am Soc Nephrol; 2006 Sep; 17(9):2402-13. PubMed ID: 16899520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. With no lysine L-WNK1 isoforms are negative regulators of the K+-Cl- cotransporters.
    Mercado A; de Los Heros P; Melo Z; Chávez-Canales M; Murillo-de-Ozores AR; Moreno E; Bazúa-Valenti S; Vázquez N; Hadchouel J; Gamba G
    Am J Physiol Cell Physiol; 2016 Jul; 311(1):C54-66. PubMed ID: 27170636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WNK4 is indispensable for the pathogenesis of pseudohypoaldosteronism type II caused by mutant KLHL3.
    Susa K; Sohara E; Takahashi D; Okado T; Rai T; Uchida S
    Biochem Biophys Res Commun; 2017 Sep; 491(3):727-732. PubMed ID: 28743496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kelch-like 3/Cullin 3 ubiquitin ligase complex and WNK signaling in salt-sensitive hypertension and electrolyte disorder.
    Sohara E; Uchida S
    Nephrol Dial Transplant; 2016 Sep; 31(9):1417-24. PubMed ID: 26152401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The WNK1 and WNK4 protein kinases that are mutated in Gordon's hypertension syndrome phosphorylate and activate SPAK and OSR1 protein kinases.
    Vitari AC; Deak M; Morrice NA; Alessi DR
    Biochem J; 2005 Oct; 391(Pt 1):17-24. PubMed ID: 16083423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cheminformatics Analysis of Dynamic WNK-Inhibitor Interactions.
    Kuenemann MA; Fourches D
    Mol Inform; 2018 Jul; 37(6-7):e1700138. PubMed ID: 29473325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired degradation of WNK1 and WNK4 kinases causes PHAII in mutant KLHL3 knock-in mice.
    Susa K; Sohara E; Rai T; Zeniya M; Mori Y; Mori T; Chiga M; Nomura N; Nishida H; Takahashi D; Isobe K; Inoue Y; Takeishi K; Takeda N; Sasaki S; Uchida S
    Hum Mol Genet; 2014 Oct; 23(19):5052-60. PubMed ID: 24821705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a Class of WNK Isoform-Specific Inhibitors Through High-Throughput Screening.
    Chlebowicz J; Akella R; Humphreys JM; He H; Kannangara AR; Wei S; Posner B; Goldsmith EJ
    Drug Des Devel Ther; 2023; 17():93-105. PubMed ID: 36712947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Properties of WNK1 and implications for other family members.
    Lenertz LY; Lee BH; Min X; Xu BE; Wedin K; Earnest S; Goldsmith EJ; Cobb MH
    J Biol Chem; 2005 Jul; 280(29):26653-8. PubMed ID: 15883153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WNK1 and WNK4 modulate CFTR activity.
    Yang CL; Liu X; Paliege A; Zhu X; Bachmann S; Dawson DC; Ellison DH
    Biochem Biophys Res Commun; 2007 Feb; 353(3):535-40. PubMed ID: 17194447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural and biochemical characterization of the KLHL3-WNK kinase interaction important in blood pressure regulation.
    Schumacher FR; Sorrell FJ; Alessi DR; Bullock AN; Kurz T
    Biochem J; 2014 Jun; 460(2):237-46. PubMed ID: 24641320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WNK kinases regulate thiazide-sensitive Na-Cl cotransport.
    Yang CL; Angell J; Mitchell R; Ellison DH
    J Clin Invest; 2003 Apr; 111(7):1039-45. PubMed ID: 12671053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WNK kinases and blood pressure control.
    Deaton SL; Sengupta S; Cobb MH
    Curr Hypertens Rep; 2009 Dec; 11(6):421-6. PubMed ID: 19895753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WNK1 regulates phosphorylation of cation-chloride-coupled cotransporters via the STE20-related kinases, SPAK and OSR1.
    Moriguchi T; Urushiyama S; Hisamoto N; Iemura S; Uchida S; Natsume T; Matsumoto K; Shibuya H
    J Biol Chem; 2005 Dec; 280(52):42685-93. PubMed ID: 16263722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intersectin links WNK kinases to endocytosis of ROMK1.
    He G; Wang HR; Huang SK; Huang CL
    J Clin Invest; 2007 Apr; 117(4):1078-87. PubMed ID: 17380208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of WNK1 knockout cell lines by CRISPR/Cas-mediated genome editing.
    Roy A; Goodman JH; Begum G; Donnelly BF; Pittman G; Weinman EJ; Sun D; Subramanya AR
    Am J Physiol Renal Physiol; 2015 Feb; 308(4):F366-76. PubMed ID: 25477473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.